secwatch.observer — SEC 8-K summary
======================================

Issuer:     CATALYST PHARMACEUTICALS, INC. (CPRX)
CIK:        0001369568
Form:       8-K
Filed at:   2025-11-05T23:59:59+00:00
Accession:  0001193125-25-267038
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Catalyst Pharma Q3 rev $148.4M (+17% YoY); raises FY25 revenue guidance to $565-$585M
--------------------------------------------------------------------------------

- GAAP net income $52.8M ($0.42 diluted EPS); non-GAAP net income $86.1M ($0.68 diluted EPS).
- FIRDAPSE net revenue $92.2M (+16.2% YoY); AGAMREE net revenue $32.4M (+115.2% YoY).
- FYCOMPA net revenue $23.8M (-25.8% YoY) as first generic tablet entered market in Q2 2025.
- Cash and equivalents $689.9M as of Sep 30, 2025; $200M share repurchase program announced.
- Full-year AGAMREE guidance raised to $105-$115M; FYCOMPA guidance raised to $100-$110M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1369568/000119312525267038/0001193125-25-267038-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1369568/000119312525267038/d56925d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-267038

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer